This product is a recombinant human antibody that recognizes GLP1R. 3F52 specifically binds to human and cynomolgus monkey GLP-1R. 3F52 blocked the GLP-1 binding site of the ECD directly and thereby acts as a competitive antagonist of native GLP-1. mAb 3F52 functioned as a neutral antagonist.
Figure 1 MAb 3F52 selectively inhibits GLP-1 but not glucagon, GIP or GLP-2 receptor.
(a,b) Receptor radioligand competition binding experiments with membranes of BHK cells stably over-expressing human GLP-1R (a) and GCGR (b), respectively. (a) Displacement of 125I-GLP-1 from GLP-1R by GLP-1 and mAb 3F52. (b) 125I-glucagon is displaced from GCGR by glucagon but not mAb 3F52. (c,d) Cell-based cAMP Flashplate assay with BHK cells stably over-expressing human GLP-1R (c), GCGR, GIPR and GLP-2R (d). (c) GLP-1 induces concentration-dependent increase of intracellular cAMP, and this can be inhibited by mAb 3F52 in a concentration-dependent manner, whereas mAb 3F52 alone is completely inactive. (d) MAb 3F52 does not reveal any influence on GCGR-, GIPR- and GLP-2R-mediated cAMP accumulation induced by EC80 concentration of the respective ligands. Values have been normalized to the response of the corresponding ligand (GCG, GIP, GLP-2) in the absence of mAb 3F52.
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P.,... & Gandhi, P. S. (2016). Structural insight into antibody-mediated antagonism of the glucagon-like peptide-1 receptor. Scientific reports, 6, 26236.
Figure 2 Characterization of Fab 3F52 by 125I-GLP-1 competition binding of GLP-1R from different species.
(a–e) Membranes of BHK cells stably over-expressing GLP-1R specifically bind to 125I-GLP-1, which can be displaced by native GLP-1 at all tested receptor species, whereas Fab 3F52 selectively reveals displacement only at human (a) and cynomolgus monkey (b) GLP-1R, and no competition is recorded at mouse (c), rat (d) and pig (e) GLP-1R.
Hennen, S., Kodra, J. T., Soroka, V., Krogh, B. O., Wu, X., Kaastrup, P.,... & Gandhi, P. S. (2016). Structural insight into antibody-mediated antagonism of the glucagon-like peptide-1 receptor. Scientific reports, 6, 26236.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-2540z-F(E) | Recombinant Anti-Human GLP1R Antibody Fab Fragment | ELISA, FuncS | Fab |
HPAB-0384-YC-F(E) | Human Anti-GLP1R Recombinant Antibody; Fab Fragment (HPAB-0384-YC-F(E)) | ELISA, FC, FuncS | Human Fab |
HPAB-0385-YC-F(E) | Mouse Anti-GLP1R Recombinant Antibody (clone m38C2); Fab Fragment | FuncS | Mouse Fab |
HPAB-0386-YC-F(E) | Human Anti-GLP1R Recombinant Antibody (clone h38C2); Fab Fragment | FuncS | Humanized Fab |
HPAB-0189CQ-F(E) | Human Anti-GLP1R Recombinant Antibody (clone 3F52); Fab Fragment | ELISA, IHC, Block | Chimeric (mouse/human) Fab |
There are currently no Customer reviews or questions for HPAB-0189CQ. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.